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In Finland, the number of medicines with marketing au-
thorisation is constantly growing, and therefore the
range of medicines available is greater than ever before.
Despite that, situations arise now and then where suit-
able treatment is not available, and the medicine needed
for treating a patient does not have a marketing autho-
risation. The Medicines Act makes allowance for such
exceptional cases. It provides for a special permit being
issued to an unauthorised medicine for administration
to a specific patient for particular medicinal purposes.
The plethora of individual special permits for com-
passionate use – 17 000 decisions per annum – raises
the question of whether the need for medicines lacking
marketing authorisation at such a great rate is genuine
and warranted. A closer inspection of the permits re-
veals that, contrary to assumptions, the underlying
cause is not so often the need to resort to an extraordi-
nary, special form of treatment, but rather regular treat-
ment of a small group of patients.
Some of the special-permit medicines have never
been granted marketing authorisation in Finland, either
due to the medicine being at an early stage of clinical
use, or the rarity of the illness. After the marketing au-
thorisation of a medicine has been cancelled on health
or safety grounds, its use may well be warranted as the
therapy of choice for individual patients under certain
circumstances. Particularly in these cases, the responsi-
bility and expertise of the treating physician is empha-
sised, when deciding on the course of treatment. The ac-
quisition of correct information on the efficacy and safe-
ty of a medicine might in such cases be laborious, be-
cause of which the supervision of the treatment requires
greater care than usual.
It is worth noting that one third of all special permit
decisions concerned medicines whose marketing autho-
risations had expired as a result of decisions made by
pharmaceutical companies. Old, relatively unpopular
medicinal preparations, the sales of which are no longer
considered competitive, are constantly being removed
from the market. Product ranges, their variety of
strengths and dosage forms, are now more than ever be-
fore under strict critical scrutiny for competitiveness. As
a result, some of our long-established drug treatments
are finally excluded from the marketing authorisations
system. This phenomenon occurs easily in small lan-
guage and market areas such as Finland. The only
means available to the National Agency for Medicines
for influencing the retention of a medicine on the mar-
ket is exempting it from the annual marketing authori-
sation fee.
Erkki Palva
PROFESSOR, HEAD OF DEPARTMENT
Department of Safety & Drug Information
National Agency for Medicines
Special permits to fill the gaps in the 
availability of medicines
Editorial
Summary 
Translation Sari Jay
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Crohn’s disease is a chronic inflam-
matory bowel disease which may in-
volve the entire gastrointestinal
canal, even though the changes are
more generally situated at the end
of the small intestine and in the cae-
cum and ascending colon. Cases in-
volving the small intestine exclusive-
ly total about 30%, and those in-
volving the large intestine exclusive-
ly total about 25% of all the cases.
According to the clinical picture, the
disease is defined as stricturing, fis-
tulous and non-perforating, non-
stricturing, or of the colitis type (Vi-
enna classification); the selection of
medical treatment also depends on
the subtype of the disease. Accord-
ing to present understanding,
Crohn’s disease is an immunoregu-
latory bowel control disorder in ge-
netically susceptible individuals,
characterised by a triggering factor,
usually a bowel infection, and as a
result of which the immunological
tolerance to the normal intestinal
bacterial flora is destroyed. This re-
sults in a continuous active inflam-
matory response, and due to the in-
creased permeability of the intesti-
nal mucosa the intestine “leaks”
bacterial antigens, which again in
their turn activate the T lympho-
cytes and macrophages of the lami-
na propria. The apoptosis of the ac-
tivated T lymphocytes is normally
an important control mechanism of
the inflammatory response, which in
Crohn’s disease is reduced, thus
maintaining and increasing the
chronic state of the inflammation.
The activating macrophages of the
T cells increase the inflammatory re-
action even further, producing
proinflammatory cytokines, such as
interleukin 1, TNF and interleukin
12. A chronic active inflammation
results in tissue injuries and abdom-
inal pain, diarrhoea and bleeding.
The incidence of Crohn’s disease is
14–15 times greater in first degree
relatives than in the unrelated, and
the concordance of monozygotic
twins vis à vis the disease is 67%.
The first gene exposing the patient
to the disease, CARD 15, has been
found on chromosome 16. It ex-
plains a relatively small proportion
of the origin of Crohn’s disease and
the specification of the mutation has
no clinical significance in the assess-
ment of the prognosis or the treat-
ment of the disease.
Medical treatment
The medical treatment of Crohn’s
disease remains empirical. Two ap-
proaches can be distinguished: 1) al-
leviation of the active disease, i.e.
induction of remission and 2) main-
tenance treatment of the remission
(Table 1). The planning of the treat-
ment requires a definitive diagnosis
of the disease and a review of the
extent, activity and potential com-
plications of the disease. In addition
to symptoms, the diagnosis is, to a
large extent, based on endoscopic
examinations. Evaluation of re-
sponse has for a long time been
based on various indices of symp-
toms, the most commonly used one
of which is the CDAI (Crohn’s dis-
ease activity index). Numerous indi-
rect indicators determined from the
serum or the faeces (e.g. calculation
of calprotectine, α1-antitrypsin and
lactoferrin levels in the faeces) have
been developed which could replace
endoscopic examinations.
Induction of remission
Corticosteroids constitute the pri-
mary treatment of active Crohn’s
disease (1, 2). As many as 80% of
the patients achieve a clinical remis-
sion through oral prednisolone ther-
apy within 4 weeks (3, 4). In the in-
duction of remission, budesonide at
9 mg/day is almost as effective as
New approaches in the treatment of Crohn’s disease
Martti Färkkilä
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Even though the aetiology and pathogenesis of Crohn’s disease remain unknown, the disease has
been the object of intensive medical research. Novel biological response modulators have been in-
troduced in clinical practice and the position of old drugs such as 5-ASA preparations has been re-
viewed. The new biological drugs are effective albeit costly, and they require well-defined patient
treatment plans including, above all, objective indicators of the response and criteria for continu-
ing the treatment. The aims of treatment are also changing: as well as freedom of the patient from
symptoms, endoscopic response to treatment is also an objective. Endoscopic remission has been
found to improve the patients’ quality of life and to decrease hospitalisation as well as, naturally,
the need for surgery.
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prednisone 40 mg, but it has fewer
adverse reactions. Budesonide is
nevertheless appropriate only in the
treatment of the terminal ileum
and/or the ascending colon in
Crohn’s disease, whereas neither of
the corticosteroids is superior to a
placebo in the maintenance treat-
ment of the disease. Metronidazole
among the antibiotics has been
proven effective in colitis or ileo
colitis in active Crohn’s disease, but
apparently not in the form of the
disease involving exclusively the
small intestine (5, 6). The efficacy
of aminosalicylic acid (5-ASA)
preparations in active Crohn’s dis-
ease is very small. Six randomised
placebo-controlled studies (7) have
been published on the efficacy of
mesalazine in mild and moderate
Crohn’s disease; a significant differ-
ence vis à vis the placebo was only
found in two of them, in which a
daily dose of ≥ 3.2 g was used. In
the studies which compared
mesalazine with prednisone the re-
sponse to the 5-ASA preparations
was found to be significantly poorer
(7). Consequently, sulfasalazine and
mesalazine are rather more appro-
priate in the maintenance treatment
of mild ileocolic Crohn’s disease or
Crohn’s colon. Ciclosporin has been
found to be ineffective in active
Crohn’s disease. 
Immunosuppressive treatment
with, for instance, azathioprine or
methotrexate is of no great impor-
tance in the acute state of the dis-
ease due to the slow response to
them. They are nevertheless excel-
lent in the treatment of the chroni-
cally active disease and in mainte-
nance treatment, and the therapy is
usually introduced already at the
acute stage in combination with
drugs to induce remission (compare:
treatment of remission).
The concentrations of tumor
necrosis factor alpha (TNFα) are el-
evated in Crohn’s disease. TNFα is
a proinflammatory cytokine which
partakes in e.g. the activation of
macrophages and the cytokine syn-
thesis thereby potentiating the in-
flammatory response. TNFα anti-
bodies promote the apoptosis of the
activated T cells, thereby also inter-
rupting the inflammation cascade.
Good results have been obtained
with a TNFα antibody, infliximab,
in the treatment of active moderate
to severe Crohn’s disease resistant
to treatment. A clinical response (a
drop of over 70 points in CDAI)
was obtained with a single infusion
(5 mg/kg) in 81% of the patients,
compared with 17% obtained with
a placebo, and remission (CDAI be-
low 150) was achieved in 33% and
4% of the patients, respectively,
within four weeks (8). Good results
have been obtained in fistulous ac-
tive Crohn’s disease by using intra-
venous doses of infliximab 5 mg/kg
in series of 0, 2 and 6 weeks (9).
About 50% of the active fistulas
close up after a series of three infu-
sions administered over a period of
six weeks.
Maintenance of remission
The induction of a remission is suc-
cessful in the majority of acute cases
of Crohn’s disease, but the mainte-
nance of remission is considerably
more difficult.
Drugs used in the maintenance
treatment of Crohn’s disease are
outlined in Table 2, the most com-
monly used and most effective ones
of which are the immunomodula-
tors: azathioprine and mercaptop-
urine, and also methotrexate.
Thiopurines
A meta-analysis of the efficacy of
azathioprine and mercaptopurine in
the treatment of Crohn’s disease
shows the efficacy of thiopurines in
the active disease to be 3.09-fold
(95% CI 2.35–3.91), and in the
maintenance of remission it was
shown to be 2.27-fold (95% CI
1.76–2.93) compared with the
placebo (10). They have also been
found effective in the treatment of
fistula and thus constitute the pri-
mary treatment in the chronically
active fistulous disease (10). When
using adequate doses, it is also pos-
sible to achieve a complete endo-
scopic remission with thiopurine
therapy (11). The recommended
doses are: azathioprine 2.0–2.5
mg/kg/day and mercaptopurine
(MP) 1–1.5 mg/kg/day. Azathioprine
is a prodrug which is nonenzymati-
cally metabolised to mercaptop-
urine. Somewhat fewer dyspeptic
adverse reactions are associated
with mercaptopurine (Table 3). Seri-
Table 2.  Maintenance of  remission in Crohn’s disease
Location of disease Primary therapy Secondary therapies
Ileocaecal/ileal disease azathioprine, methotrexate, infliximab
mercaptopurine
Colon/colorectal disease metronidazole, methotrexate, infliximab
sulfasalazine 4–6 g
azathioprine
Fistulous disease metronidazole, infliximab
azathioprine, 
mercaptopurine, 
fluoroquinolones
Table 1. The treatment of active Crohn’s disease. Induction of remission.
Location of disease Primary therapy Secondary therapies
Ileocaecal/ileal disease Prednisone, budesonide Antibiotics, sulfasalazine 
glucocorticoids, azathio-
prine, infliximab
Colon/colorectal disease 1) metronidazole Antibiotics, glucocorticoids
2) sulfasalazine azathioprine,mercapto-
3) 5-ASA (postoperatively) purine, infliximab
Fistulous disease metronidazole, azathioprine, infliximab
mercaptopurine
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ous adverse reactions associated
with thiopurines have resulted in
the withdrawal of treatment in
about 9% of clinical studies. The
most common adverse reactions in-
clude allergic reactions, bone mar-
row depression (2–3%) and pancre-
atitis (3–7%). In theory, the mercap-
topurine metabolite, thioguanine (at
40 mg/day), may have fewer adverse
reactions compared with mercap-
topurine and azathioprine, but it al-
so causes leukopenia and hepatic
enzyme elevation as well as pancre-
atitis (12), and there is no proof of
safety on long-term use. The prima-
ry maintenance treatment of exten-
sive, chronic active or fistulous or
densely recurring Crohn’s disease is
azathioprine or mercaptopurine.
Methotrexate
If the patient does not tolerate
thiopurines, the alternative is
methotrexate. The proof of its effi-
cacy is nevertheless less assured
than that of azathioprine or mer-
captopurine. In steroid-dependent
(dose ≤ 12.5 mg/day for over 3
months) chronically active disease,
39.4% of the patients on intramus-
cular methotrexate (25 mg/week)
achieved a remission calculated by
the CDA index and were able to
abandon steroid therapy altogether,
whereas the corresponding figure in
the placebo group was 19.1%.
However, the study only lasted for
40 weeks and was not endoscopical-
ly controlled (13). 65% of the pa-
tients who had earlier responded to
methotrexate therapy remained in
remission when the methotrexate
therapy was continued at intramus-
cular doses of 15 mg/week, com-
pared with 39% of the patients on
placebo (14).
Aminosalicylic acid preparations 
The efficacy of mesalazine prepara-
tions in the maintenance treatment
of Crohn’s disease is debatable. A
total of 9 randomised placebo-con-
trolled studies of the maintenance
treatment have been published com-
prising about 1,500 patients in all
(15). The number of relapses in the
placebo group in the studies has
varied between 32% and 71% (me-
dian of 53%), compared with
22%–64% in the treatment groups
(median of 45%). In six of the stud-
ies, a statistical difference between
the control group and the treatment
group was not possible to achieve.
The daily doses used were 1–4
g/day, a median of 2.4 g. A meta-
analysis (16) showed that in studies
where its effect was reviewed the ef-
ficacy of mesalazine therapy did not
differ statistically from the placebo
in the maintenance of remission in-
duced by medical treatment; it was
only postoperatively that the 5-ASA
preparations were more effective
than the placebo in sustaining the
remission. In the light of the benefit
shown the present role of 5-ASA
preparations in the treatment of
Crohn’s disease should be critically
reassessed. What, then, are the ther-
apeutic indications of these prepara-
tions in Crohn’s disease? In the
treatment of active Crohn’s disease,
very high doses of sulfasalazine (4–6
g/day) may be effective when treat-
ing the mild or moderate colonic
type of Crohn’s disease, and doses
of mesalazine in excess of 3 g may
be effective in the treatment in
Crohn’s disease of the ileum (17). In
maintenance treatment, the only
definite proof for mesalazine is in
the prevention of postoperative re-
lapses at daily doses of 3 g, and
consequently, the current extensive,
aimless use in maintenance therapy
in Crohn’s disease is unfounded. Re-
sults for Crohn’s disease are not
available on the chemoprevention of
dysplasias or colorectal cancer by
the use of 5-ASA preparations.
Infliximab
A study comprising 335 patients has
been published on the efficacy and
safety of use of infliximab in the
maintenance treatment of Crohn’s
disease (18). The Crohn’s disease
patients selected had a CDAI of
220–400 and they had responded (a
drop of over 70 points in the CDAI)
to the first infusion of infliximab 5
mg/kg after 2 weeks of its adminis-
tration. This was 59% of the origi-
nal selection of patients. The pa-
tients were randomised into three
categories of treatment, where one
group received a placebo, another
infliximab in the 2nd and 6th week
and twice thereafter at 8-week inter-
vals. The third group received the
same induction therapy, but the
maintenance treatment consisted of
10 mg/kg at 8-week intervals. The
number of patients remaining in re-
mission (CDAI < 150) was analysed
at week 30, and at week 54 the
number of patients in whom the dis-
ease had recurred was established.
21% of the patients on placebo
were in remission, 39% of those in
group II (maintenance treatment 5
mg/kg) and 45% in group III (main-
tenance treatment 10 mg/kg). Com-
pared with the placebo, infliximab
therapy (groups II and III) was 2.7-
fold (95% CI 1.6–4.6) more effec-
tive, but the doses of 5 and 10
Table 3. The main undesirable effects of drugs used in the treatment of Crohn’s
disease
Drug The most common adverse reactions
Sulfasalazine Headache, abdominal pain, nausea, rash, fever, hepatitis,
haemolytic anaemia, leucopenia, agranulocytosis, pancreatitis
Mesalazine Headache, nausea, diarrhoea, pancreatitis, hepatitis, 
interstitial nephritis
Corticosteroids Moon face, acne, osteoporosis, weight increase, striae, 
hypertension, hyperglycaemia, cataract
Thiopurines Nausea, abdominal pain, rash, leucopenia, pancreatitis,
hepatitis
Methotrexate Nausea, abdominal pain, bone marrow depression, stomatitis,
tiredness, fever, hepatitis, pneumonitis, teratogenic
Infliximab Immediate: infusion reactions, dyspnoea, rashes, urticaria, 
anaphylaxis, nausea, diarrhoea, abdominal pain
Delayed reaction: increased sensitivity to infections, opportunis-
tic infections, changes in hepatic values, autoantibodies, 
clinical picture of the SLE type
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mg/kg did not differ from each oth-
er statistically. A relatively high
number of adverse reactions oc-
curred, and 9% of the patients
withdrew themselves from the
study. Infections requiring antibiotic
therapy were exhibited in an aver-
age of 32% and severe infections in
4% of the patients. 17% of the pa-
tients experienced infusion reac-
tions. Based on the results of this
study, it can be concluded that the
likelihood of patients with active
Crohn's disease previously not
treated with infliximab reaching re-
mission at week 30 is 23% (5
mg/kg). The achieved response to
treatment and its duration are,
among other things, influenced by
the formation of antibodies to in-
fliximab (19). The antibodies also
increase the risk of infusion reac-
tions. The formation of antibodies,
again, is influenced by the immun-
omodulatory medication in use: cor-
ticosteroids, thiopurines and metho-
trexate including the number of in-
fusions administered. Patients on
immunomodulatory treatment have
fewer infusion reactions, a superior
primary response to treatment and a
longer duration of response. In ad-
dition to the formation of antibod-
ies, smoking significantly decreases
the treatment response achieved by
both azathioprine and infliximab,
actually to such an extent that there
is reason to question the treatment
with these drugs of a smoking pa-
tient with Crohn's disease.
In whom is infliximab therapy
justified, then? According to a Euro-
pean (20) and an American (21)
treatment recommendation, inflix-
imab is primarily indicated for the
treatment of patients in whom other
treatments (corticosteroids and im-
munomodulators) have not pro-
duced an adequate response, or if,
due to serious adverse recations, im-
munomodulatory drugs cannot be
used and the disease cannot be
treated surgically, or for the treat-
ment of patients with a fistulous
disease with no response to custom-
ary treatment (20). The criteria for
maintenance treatment have never-
theless changed in view of the previ-
ous European recommendation. If
induction therapy produces a defini-
tive response, then maintenance
therapy is justified, but the continu-
ation of treatment in patients who
have not responded to treatment is
unfounded. A recommendation for
a criterion in infliximab therapy to
be followed within the Helsinki-
Uusimaa Hospital District is out-
lined in Table 4 (20-22). In the ab-
sence of antibodies, adequate im-
munomodulatory treatment is a pre-
requisite for the introduction of in-
fliximab therapy. A shift to mainte-
nance treatment requires a definitive
response to treatment. It is recom-
mended that response to the mainte-
nance treatment be checked at the
latest a year after the start of the
therapy series, and a decision be
made about any continuation of
treatment.
Other TNFα antagonists and in-
hibitors. CDP571 is a humanised
monoclonal antibody of the IgG4
class. Nevertheless, in clinical stud-
ies its efficacy has been found to be
significantly poorer than that of in-
fliximab. Etanercept is a soluble fu-
sion peptide of the TNF receptor
and found to be ineffective in the
treatment of Crohn's disease.
Thalidomide inhibits TNF biosyn-
thesis by increasing the TNF mRNA
breakdown in the macrophages.
The primary treatment responses
have been relatively modest, but in
maintenance treatment, after the in-
duction of infliximab and when
thalidomide was used at 100
mg/day, over 80% of the patients
remained in remission for 12
months following the last infusion
of infliximab (23).
Further medical treatment in
Crohn's disease
The underlying causes of symptoms
exhibited by a patient with Crohn's
disease may be other than those of
disease activation. Diarrhoea after
terminal ileum resection may origi-
nally be due to malabsorption of
the bile salts, and it is effectively
treated with cholestyramine or
cholestipole. In extensive small in-
testine resection, fibre products and
loperamide may be used to slow
down the small intestine transit time
and to reduce diarrhoea and in-
crease the absorption of fluids. Re-
placement of fat-soluble vitamins is
justified on the basis of proven defi-
ciencies. Furthermore, patients with
inflammatory bowel diseases experi-
ence functional abdominal discom-
fort at least as often as healthy vol-
unteers.
Novel drugs in the treatment of
Crohn's disease
Several new biological response
modulators influencing the various
stages of the inflammatory process
are being studied in the treatment of
Crohn's disease: antibodies affecting
the differentiation of CD 4T helper
lymphocytes and lymphocyte mobil-
ity, such as natalizumab and new
TNF mediated cytokinin antibodies.
In future, the treatment of Crohn's
disease will be more by individual
combination treatment than it has
hitherto been. Even though Crohn's
disease is not curable at present, the
Table 4.  Recommendation on the use of  inf l ix imab in Crohn's disease
Helsinki  University  Central  Hospital ,  HYKS
Therapeutic  indicat ions
• extensive or fistulous Crohn's disease not responding to other treatment
Dosage
• non-penetrating disease
two infusions 5 mg/kg at 0. and 8. weeks 
• penetrating disease (fistulas)
• three infusions 5 mg/kg at 0., 2. and 6. weeks
Response control
• clinical and endoscopic evaluation of the result of treatment: 4 weeks following
the end of the course of treatment
Maintenance treatment
• if response to treatment is objective: reinfusions at 2–4 month intervals
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majority of patients can be made
symptom-free and given long-term
remission. Endoscopic remission re-
duces the patient's symptoms, im-
proves the quality of life, and de-
creases the need for hospitalisation
and surgical treatment. Neither will
the disease shorten the patient's
lifespan.
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In view of the total blood circula-
tion in the body, the kidneys are
among the most important organs,
since adverse drug reactions (ADRs)
in them may have serious conse-
quences renal circulation is approxi-
mately 25% of the body’s total
blood circulation, and the kidneys,
for their part, are responsible for the
elimination from the body of vari-
ous substances, foreign to the body,
and of waste substances introduced
via the nutrition. It is estimated that
2–3% of adverse drug effects would
be targeted at the kidneys and the
urinary tract. The estimate is sup-
ported by the reports on adverse
drug reactions received by NAM
during 1973 – September 2003
(17,608 reports), 2.1% of which
were on reactions in the kidneys or
the urinary tract.
As with other organ groups, re-
nal toxicity can be distinguished as
non-dose-dependent and unpre-
dictable reactions (idiosyncratic re-
nal toxicity), and as predictable
dose-dependent adverse reactions
(toxicity associated with the size of
dose). Direct toxicity is mostly asso-
ciated either with the direct renal
tissue damage caused by the drug,
or with changes in the renal blood
flow. Medicinal substances known
to have dose-dependent adverse ef-
fects on the kidneys include e.g. an-
tibiotics of the aminoglycoside
group, drugs intended for the treat-
ment of infections or for immuno-
suppression (amphotericin, ciclo-
sporin and vancomycin), non-
steroidal anti-inflammatory anal-
gesics, paracetamol and lithium. In
practice, the same drug groups may
also cause idiosyncratic reactions. If
the patient’s renal function is im-
paired as part of a primary disease,
then the groups of exacerbating
drugs include e.g. ACE inhibitors,
aminoglycosides, anti-inflammatory
analgesics, contrast media and an-
giotensin receptor blockers.
The most commonly reported
symptoms and diagnoses associated
with renal and urinary tract ADRs
included (reported terms in paren-
theses) symptoms indicative of renal
impairment (increased serum creati-
nine, albuminuria and abnormal re-
nal function), 69 reports; micturi-
tion pain, 66 reports; symptoms or
diagnoses indicative of direct renal
damage (acute or chronic renal fail-
ure, anuria, uremia, nephrotic syn-
drome), 63 reports; histological re-
nal damage (interstitial nephritis,
nephritis, renal tubular necrosis and
“minimal change” glomerulo-
nephritis), 29 reports; urinary reten-
tion, 29 reports; haematuria, 27 re-
ports; and urinary incontinence, 16
reports. Among the reported symp-
toms, haematuria, for example, can
be considered a rather non-specific
symptom because, in addition to the
administered medicinal substance, it
can also be associated with acute
urinary tract infection and renal or
urinary tract neoplasms.
The reports were fairly evenly
distributed among the individual
medicinal substances and their re-
spective groups. There were distinc-
tive trends among the ADRs: in-
creased creatinine values associated
with the use of ACE inhibitors (14
reports), renal damage associated
with anti-cancer drugs and especial-
ly ciclosporin, or their symptoms
(14 reports), micturition pain or
stinging sensation during micturition
associated with the use of tolfenamic
acid (31 reports), increased serum
creatinine or albuminuria associated
with the use of aurothiomalate for
the treatment of rheumatic diseases
(10 reports). Adverse reactions
caused by antibiotics were mostly
associated with interstitial nephritis,
elevated serum creatinine, renal
damage or symptoms of the onset of
renal damage reported with the use
of broad-spectrum penicillin deriva-
tives, cephalosporins and aminogly-
cosides (20 reports).
On the basis of these ADR re-
ports it is fair to say that renal dam-
age associated especially with drugs
that have been in use for a long time
is well known in clinical practice,
and any new drug safety signals
causing alarm cannot be detected
among the reported renal or urinary
tract ADRs. The evaluation of renal
adverse drug reactions or indications
of them should therefore in the fu-
ture focus on the recent medicinal
substances, especially those with a
tendency to renal accumulation and
elimination. In general, dose-depen-
dent toxicity should be monitored
especially carefully and each sus-
pected renal reaction reported to the
National Agency for Medicines.
Renal and urinary tract ADRs reported to the Na-
tional Agency for Medicines during 1973–2003
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A case of adverse drug reaction
Drug fever caused by hydroxycarbamide
Summary 
Drug fever is a rare adverse reaction
despite its being thought to occur in
as many as 10% of hospital patients
(1). The connection between fever
and an individual drug may be diffi-
cult to detect because fever as a
symptom is very common; the patient
is perhaps being treated with several
different drugs at the same time, and
a drug used for a long period of time
may also suddenly trigger fever.
Many unnecessary and costly exami-
nations can be avoided by early diag-
nosis of drug fever. Our case is a pa-
tient who was found to have drug
fever which had been triggered by hy-
droxyurea, i.e. hydroxycarbamide. 
Our own case
Our patient is a 55-year-old male
who had about seven years previous-
ly been diagnosed with a hyper-
eosinophilic syndrome associated
with skin manifestations. At the time
of diagnosis, the blood eosinophil
leukocyte count was at the level of
1500 x 106/l. The patient had no oth-
er underlying diseases, nor did his
history reveal any allergic tendencies.
The hypereosinophilic syndrome had
been treated with oral prednisolone.
It had not been possible, however, to
decrease the dose below the daily
dose of 15 mg, and since the patient
also developed osteoporosis, a deci-
sion was made to supplement the
treatment with hydroxycarbamide.
The dose of prednisolone remained at
15 mg/day up until the 31st of July,
and the dose was thereafter reduced
by 5 mg. A concomitant dose of 500
mg hydroxycarbamide twice a day
was initiated at the same time. The
dose was designed to be halved after
10 days.
On the 18th of August, i.e. less
than three weeks after commence-
ment of the treatment, the patient de-
veloped a high fever (39°C), head-
ache and myalgia. No nausea, vomit-
ing, skin changes or joint trouble oc-
curred. On arrival at the hospital the
following day the patient was fever-
ish (39.3°C), but his general condi-
tion was nevertheless fairly good. The
conjunctivae were bloodshot. There
was no stiffness of the neck, and no
other neurological findings were
made. The patient was hospitalised in
a ward for infectious diseases.
On admission, the laboratory re-
sults were fairly normal. The erythro-
cyte sedimentation rate (ESR) was
within normal limits (7 mm/h) and
the C reactive protein (CRP) slightly
elevated (33 mg/l). The blood count
was normal, the total leukocyte count
was 6.9 x 109/l, and an analysis re-
vealed the following: neutrophilic
granulocytes 81%, lymphocytes 9%,
monocytes 8%, eosinophiles 1% and
basophiles 1%. The serum hepatic
values were within normal limits, but
the lactate dehydrogenase concentra-
tion was slightly elevated (508 U/L).
Primary examinations on the spinal
cord fluid did not reveal abnormali-
ties, and bacterial staining and cul-
ture gave negative results, as also did
herpes simplex and enterovirus inves-
tigation. Epidemic nephropathy or
tularaemia antibodies were not de-
tected in the serum, and no signifi-
cant findings were made on serum
virus antibody screening. No abnor-
malities were revealed in X-rays of
the lungs and paranasal sinuses.
The CRP was at its highest on the
20th of August (45 mg/l), when ESR
was elevated to 31. Hydroxycarb-
amide therapy was discontinued on
admission to hospital, and treatment
with prednisolone was continued.
Fever abated within a couple of days,
having been 39.7°C on the 20th,
37.2°C on the 21st and 36.8°C on
the 22nd of August, the day of dis-
charge.
The patient took one tablet of
500 mg hydroxycarbamide on the
26th of August. Soon afterwards he
developed a fever with shivering and
a severe headache, i.e. the symptoms
overall bore a close resemblance to
the previous condition.
Conclusion
The patient obviously developed a
drug fever caused by hydroxycar-
bamide. A similar reaction caused by
re-exposure gives support to the role
of hydroxycarb-amide. No other
cause for the fever could be found. In
particular, viral meningitis – with
which the symptoms were perfectly
concordant – could not be diagnosed.
Hydroxycarbamide is an oral cy-
tostatic which has been in use since
the 1960’s. Its effect is based on the
DNA polymerase inhibition. Hydrox-
ycarbamide is used in haematology,
primarily in chronic myeloprolifera-
tive diseases, but also in the allevia-
tion of acute myeloblastic leukaemia,
and, in very large doses, in associa-
tion with autologous stem cell trans-
plantation in haematological and
non-haematological malignancies (2).
It is used for the treatment of sickle
cell anaemia (3) and also as an ad-
junct to other treatment, e.g. in psori-
asis and HIV infection. The drug is
well absorbed, reaches its peak blood
concentration within about two
hours and is eliminated from the
body within 24 hours. The drug is
eliminated via the kidneys. The usual
daily dose is between 0.5 and 3 g de-
pending on the patient and indica-
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tion, but the very large doses re-
quired to achieve aplasia may be as
high as 100 mg per kg of body-
weight daily (4). The drug is mostly
well tolerated and due to its short
half-life the dose is generally easy to
titrate. The general adverse reactions
include bone marrow depression and
consequent cytopaenias, gastroin-
testinal symptoms, impaired renal
function and skin reactions.
Rare adverse reactions caused by
hydroxycarbamide include febrile re-
actions (5, 6, 7, 8 and 9). However,
in only a proportion of the reported
cases has this effect been confirmed
by re-exposure. Some of the cases
have been associated with influenza-
like symptoms and, as in our case,
myalgia and shivering. The condition
in two patients with psoriasis was
complicated by palpable purpura
which corresponded histologically to
small-vein necrotising vasculitis (5).
The time between the start of the
medication and the onset of the fever
has varied greatly in the reported
cases. Lossos and Matzner describe a
patient with essential thrombocytosis
who developed a fever as quickly as
12 hours after the start of the med-
ical therapy. Moschella and Green-
wald (5) describe 60 psoriasis pa-
tients on hydroxycarbamide therapy
with a follow-up period of 18
months. Six of the patients devel-
oped a drug fever (two of whom also
developed dermal vasculitis) which
in all cases started within six weeks
of the start of the medication. The
fever typically subsided within a cou-
ple of days after discontinuation of
the drug therapy.
A drug fever can be triggered by
almost any medicine. Numerically,
most of the cases have been associat-
ed with antibiotic treatment. John-
son and Cunha (1) give a list in their
survey of the medicinal substances
generally causing drug fever, and
these include e.g. amphotericin B,
phenytoin, interferon, cephalo-
sporins, quinidine, penicillins, salicy-
lates and sulphonamides. Mack-
owiak and LeMaistre (10) report on
148 drug fever episodes during
1959–1986. Of these, 51 were com-
piled from the records of two hospi-
tals in Dallas and the rest from the
literature. The article mentions near-
ly 60 diverse medicines as fever-trig-
gering drugs; one of them is hydrox-
ycarbamide. The list also contains
old substances such as alpha-methyl-
dopa, procainamide and cimetidine.
The time between the start of the
medication and the onset of fever
varied greatly; on average it was 21
days (median of 8 days). This time
was considerably shorter with regard
to fever associated with cytostatic
agents (mean of 6 days) compared
with the other drug groups. The
mean onset of fever associated with
antibiotic treatment was about 8
days. The drug fever nearly always
ceased within 2–3 days of discontin-
uation of the drug therapy. Only
rather rarely was the fever associated
with eosinophilia in the blood (22%
of the cases) or rash (18%), and
every fourth patient exhibited myal-
gia, 16% exhibited headache. If
eosinophilia occurred, it was general-
ly mild. Tendency to atopy, female
sex or advanced age did not predis-
pose the patient to drug fever. The
researchers did not find any fever
type especially typical of drug fever.
There is no definite information
on how general fever as the adverse
reaction to a drug actually is. It is es-
timated that fever as the sole adverse
reaction would make up 3–5% of all
adverse drug reactions (11). Drug
fever is probably much more fre-
quent, at least with beta-lactams,
compared with other drugs. It is
worth suspecting fever associated
with antibiotic treatment if, during a
long antibiotic therapy lasting for
several weeks, the fever attacks con-
tinue, or the fever starts again, and if
there is no natural explanation for
its cause such as antibiotic diar-
rhoea, abscess or endocarditis.
Should rash or eosinophilia occur in
the patient at the same time, the di-
agnosis is usually easy. During drug
fever, the patient’s general condition
typically remains good in compari-
son with the level of the fever, while
shivering and other general symp-
toms do not exclude the possibility
of drug fever (1). Circulating leuko-
cytosis, elevation, significant eleva-
tion even, of ESR and CRP, and mild
elevation of hepatic values can occur
during drug fever.
The drug-fever-inducing mecha-
nism of drugs is unclear. Despite the
variety of mechanisms, supported by
the significant variation in the re-
quired period of exposure and the
fact that the fever can be caused by
very varying medicines, the most
common mechanism is considered to
lie among the various immunological
or hypersensitivity reactions caused
by the drug (1). It is suggested that
the medicinal substance or its
metabolite can act as a hapten and,
together with the body’s own pro-
teins, form antigenic structures. Anti-
gen-antibody complexes can subse-
quently release endogenous pyrogens
and cause fever. A medicinal sub-
stance or its metabolite can also re-
act directly with tissue proteins and
cause the release of pyrogens. A
third possibility is a delayed cell-me-
diated immune response. Antibodies
to the medicinal substance detected
in the blood may support the possi-
bility of drug fever, but their absence
does not exclude it.
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Products with seemingly medical
constituents, but for sale not only at
the pharmacy but also elsewhere,
have recently been confusing con-
sumers. What products are these?
Where does the line lie between a
foodstuff and a drug, and who su-
pervises what is being sold? This ar-
ticle aims at explaining the legisla-
tion and the authorities’ supervision
associated with the sale and market-
ing of foodstuffs and drugs.
What is a drug?
A drug is a product or a substance
which, when used either internally
or externally, has as its purpose to
cure, alleviate or prevent a disease
or symptoms of a disease in man or
animal. It is a product or substance
used either internally or externally
to reverse, improve or change the vi-
tal functions of human beings or an-
imals, or to unravel the reasons for
their state of health or disease.
Herbal medicinal products are
also considered to be drugs. 
... and what is a foodstuff?
In addition to the conventional
foodstuffs, these also include the
food supplements, i.e. the products
that have been supplemented with
nutrients, e.g. vitamins, for nutri-
tional purposes. Food supplements
covered by the supervision of the
authorities of the National Food
Agency in Finland form a product
group closely related to that of
drugs. A food supplement refers to a
ready packed product which is for
sale in the form of a compact, cap-
sule, pastille, tablet, pill, powder,
concentrate, extract, liquid or other
similar type of dose, which is of-
fered for sale as a foodstuff designed
to be taken in  measured small
quantities whose amount of energy
is of no significance to the diet.
The package, leaflet, advertising
or any other form of presentation of
a food substance or foodstuff should
not detail any properties associated
with the prophylaxis, treatment or
cure of human diseases; and no ref-
erence should be made to similar in-
formation.
The consumer viewpoint
Products containing substance in-
cluded in the List of medicines is-
sued by National Agency for Medi-
cines can sometimes be sold as food-
stuffs. Consequently, on the market
there may be different products con-
taining the same substances, the
manufacture and sales of which,
however, are governed by different
requirements depending on whether
the products are introduced on to
the market in accordance with the
drug legislation or the foodstuffs
legislation.
Does it matter for the consumer
whether he or she buys the product
as a drug or as a foodstuff? A valid
marketing authorisation is required
for all drugs being sold. In order to
obtain a marketing authorisation for
a drug, there are required reviews of
quality, safety and efficacy, which
are evaluated by the authorities. Af-
ter the approval of the marketing
authorisation, the safety of use of
the medicinal product is still regular-
ly evaluated. When the consumer
buys a drug, he or she is buying a
product which has undergone prior
evaluation of safety of use, efficacy
and quality, and the safety of use of
which is being constantly moni-
tored.
Products are classified by NAM
upon request
The Agency decides whether a sub-
stance or a product should be con-
sidered a drug. A classification can
be applied for by submitting a clas-
sification request, the contents of
which are discussed on the website
of the National Agency for Medi-
cines. The classification decision is
made individually for each product
and the product is classified either
as a drug , non-drug or a medical
device. The decision is influenced by
both the constituents of the product
and its indication for use. If the
product is used according to a drug
specification, its indication for use is
medical. Further information on the
classification procedure and deci-
sions of classification made by the
National Agency for Medicines can
be found on the Agency’s website
http://www.nam.fi/english/laws/clas-
sification/application.html
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Once the classification decision
is made
Once a product has been classified
as a drug, it may not be sold as a
foodstuff. A marketing authorisation
application must be submitted for a
product classified as a drug before it
can be introduced on to the market.
The entrepreneur is responsible for
the sale of his or her product, for
the correct choice of a sales channel
and for ensuring that the product
classified as a drug is removed from
the shelves of shops selling food-
stuffs. The supervisory authorities
may interfere if the product is sold
illegally.
Supervision of marketing of
medicinal products
Only drugs referred to in the Medi-
cines Act may be advertised or mar-
keted as drugs. Marketing to the
public and marketing to health care
personnel are distinguished from
each other. If the drug marketing in-
volves any illegal procedures, the
National Agency for Medicines may
impose a ban on any further mar-
keting. The Agency may also stipu-
late that the party banned from
marketing submits a correction of
marketing to the Agency if consid-
ered necessary in view of drug safety
risks. The demand for a correction
may be reinforced by a default fine.
In addition to the supervision
carried out by the authorities, drug
marketing is also governed by inde-
pendent supervision by the pharma-
ceutical industry itself. Pharma In-
dustry Finland (PIF) is an associa-
tion promoting issues associated
with the industrial policy of the
medical research industry. It also
publishes drug marketing guidelines
in the form of a compilation of ad-
vice intended for the use of the
pharmaceutical industry itself and
based on both national and interna-
tional legislation governing drug
marketing. The member companies
of Pharma Industry Finland (PIF)
are bound by common consent to
follow the guidelines. Within the as-
sociation, the adherence to the drug
marketing guidelines is supervised
by the Supervisory Commission for
the Marketing of Medicinal Prod-
ucts and, subject to it, two inspec-
tion committees. Not all pharmaceu-
tical companies are members of
Pharma Industry Finland (PIF).
Important  legislat ion
The Act on Foods (361/1995 including
amendments)
Ministry of Trade and Industry Decree
on Food Supplements (571/2003)
Decree on the Labelling of Foodstuffs
(794/1991 including amendments)
Medicines Act (395/1987 including
amendments)
National Agency for Medicines Deci-
sion concerning the list of medicinal
substances and herbal remedies
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The aim of the endoprosthesis regis-
ter by the National Agency for Medi-
cines is to ensure the quality of endo-
prostheses and the safety of patients
in Finland. The purpose of the new
registration system for implant data
is to improve the contents of infor-
mation in the register as to serve the
development of endoprosthetics.
The results of endoprosthetic
surgery have improved considerably
during recent years. New implant
materials and new resurfacing hip
systems have been introduced. A re-
view of the present registration sys-
tem of endoprosthesis data is neces-
sary in order to reach the aim in the
best possible way. Several publica-
tions and indisputable proof are
available of the benefits of analysis
of registered endoprosthetic data. In
the 1990s, following the results of
Norwegian and Finnish analyses, a
few cementless prostheses were re-
moved from use owing to poor sta-
bility. 
Up until now the registration of
implant data has been based on short
codes used for inserting the implant
data into the endoprosthesis register.
The codes have not always indicated
the manufacturer, the importer or the
material of the implant. The addi-
tional information associated with
the code has often consisted only of
the name of the model. In the origi-
nal coding system, all implants by
one and the same manufacturer were
coded with the same initial number,
but this coding system was subse-
quently abandoned owing to the
large number of implant models.
Common codes were initially de-
signed for the various parts of hip
and knee prostheses, but the system
was changed in 1996 to separate
storage of the various parts. Informa-
tion on the internal parts of the ac-
etabular liners of hip prostheses or
femurs heads have nevertheless not
been registrated separately. This has
created a problem as different parts
can be combined fairly freely.
For the design of the system and
outlining of the various needs, con-
sultation was sought, for example,
with representatives of arthroplasty
surgery, implant importers and bar
code companies. There are in total
13 implants import companies in
Finland. 
Implant model register and other
improvements
More detailed information on im-
plants will in the future be extensive-
ly collected in the model register, the
information collection system will be
improved and the data contained in
the register will be expanded.
The data on implant models fitted
after 1996 have been inserted in the
model register with their old codes.
The new coding system will be based
on the use of product numbers (refer-
ence numbers) for each implant. The
model register will contain informa-
tion on all parts of the endoprosthe-
ses, details of manufacturers and im-
porters and also details on the mater-
ial, design and fixing properties of
the implants. The model register will
in future allow for the analysis of
durability curves in accordance with
each individual property of the endo-
prosthesis. Data on different fixing
cements, commercial bone transplant
preparations and core plugs will also
be available from the register. It is
important to focus attention on the
monitoring of bone transplant prod-
ucts, because associated legislation is
under preparation.
Information on implants in the
endoprosthesis register will be in the
form of product numbers, on which
the model register is based. The use
of product numbers will ensure the
correctness of implant product infor-
mation. 
The report forms will be reviewed
and a separate form will be designed
for each prosthesis. Electronic ver-
sions of the report forms will be pre-
pared.
In future, each implant will also
have a lot number stored, by which
each item inserted during an opera-
tion can be identified and traced
down to the manufacturing date and
lot. Packaging bar codes (product
and lot numbers) can also be used
for storing, which reduces defects.
All different parts of the prostheses
will be stored with their own specific
product and lot numbers, which will
also improve the quality of the infor-
mation. New report sheets will also
be introduced for improved accuracy
in the storing of information regard-
ing bone transplants and fixing mate-
rials.
The planning of the reformed reg-
ister has been focussed especially on
the question of which issues would
be most appropriately stored nation-
ally and which ones should be associ-
ated with the data collected at the ac-
tual operation unit. In the work of
reform, particular attention has been
directed at the correctness of data in
the model register. It is important
that in future the details of each new
model be obtained from the importer
and made available in the model reg-
ister even before the endoprosthesis
is introduced on to the market and
its sale begins in Finland.
Consequently, collection of data
for the model register has already be-
gun. It is intended for introduction
by the summer of 2004. A review of
the report sheets will begin thereafter.
The new forms will in future also be
used for the registering of data on
new implants (hip fracture prosthe-
ses, vascular prostheses, spinal pros-
theses and cochlear implants).
Translation Mervi Moisander
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